VERAXA Biotech (NASDAQ: VRXA), a developer of next-generation antibody-based cancer therapies, is implementing U.S. Food and Drug Administration-aligned New Approach Methodologies (NAMs) across its preclinical research and development programs, according to a company update. The move could accelerate clinical advancement, reduce development costs and timelines, and significantly reduce animal testing, the company said.
The company has built a panel of NAMs to characterize and de-risk its pipeline of BiTAC-based T cell engagers, antibody-drug conjugates, and bispecific antibody-drug conjugates. In a notable demonstration, VERAXA evaluated its lead BiTAC-TCE and bsADC candidates using an ex vivo panel of 10 low-passage patient-derived xenograft models of non-small cell lung cancer. That panel required about 10 mice in total, compared with an estimated 200 or more for comparable in vivo efficacy studies.
Across the panel, the combined BiTAC consistently induced potent T cell-mediated killing, supporting the company’s dual-targeting approach and demonstrating how its NAM strategy can reduce animal use and preclinical cycle time without compromising clinical relevance. The full press release is available at https://ibn.fm/9YRJw.
The significance of this announcement lies in its potential to reshape preclinical drug development, where animal testing has long been a costly, time-consuming, and ethically contentious bottleneck. By aligning with FDA-endorsed NAMs, VERAXA is positioning itself at the forefront of a regulatory and scientific shift toward more human-relevant testing methods. If widely adopted, such approaches could speed up the delivery of new cancer therapies to patients while substantially reducing the number of animals used in research.
VERAXA was founded on scientific breakthroughs made at the European Molecular Biology Laboratory (EMBL), a world-renowned institution known for pioneering life science research and cutting-edge technology. The company is building a premier engine for the discovery and development of next-generation antibody-based therapeutics, including bispecific T cell engagers, bispecific ADCs, and other innovative formats. BiTAC is a registered trademark of VERAXA Biotech GmbH.
Investors and industry observers can find the latest news and updates relating to VRXA in the company’s newsroom at http://ibn.fm/VRXA. The announcement was distributed through BioMedWire, a specialized communications platform focused on the biotechnology, biomedical sciences, and life sciences sectors. BioMedWire is one of more than 75 brands within the Dynamic Brand Portfolio at IBN, which delivers wire solutions through InvestorWire, article and editorial syndication to 5,000+ outlets, press release enhancement, social media distribution, and tailored corporate communications solutions. For full terms of use and disclaimers applicable to all content provided by BioMedWire, visit https://www.BioMedWire.com/Disclaimer.
